Literature DB >> 19034905

The combination of monoclonal antibodies and conventional chemotherapy for children with malignant lymphoma: Opportunities and challenges.

John T Sandlund1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19034905      PMCID： PMC2857692          DOI： 10.1002/pbc.21857

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


× No keyword cloud information.
  14 in total

1.  Ifosfamide/carboplatin/etoposide (ICE), an effective salvaging therapy for recurrent malignant non-Hodgkin lymphoma of childhood: a Pediatric Oncology Group phase II study.

Authors:  F H Kung; M B Harris; J P Krischer
Journal:  Med Pediatr Oncol       Date:  1999-03

2.  Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.

Authors:  Wolfgang Hiddemann; Michael Kneba; Martin Dreyling; Norbert Schmitz; Eva Lengfelder; Rudolf Schmits; Marcel Reiser; Bernd Metzner; Harriet Harder; Susanna Hegewisch-Becker; Thomas Fischer; Martin Kropff; Hans-Edgar Reis; Mathias Freund; Bernhard Wörmann; Roland Fuchs; Manfred Planker; Jörg Schimke; Hartmut Eimermacher; Lorenz Trümper; Ali Aldaoud; Reza Parwaresch; Michael Unterhalt
Journal:  Blood       Date:  2005-08-25       Impact factor: 22.113

3.  CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

Authors:  Michael Pfreundschuh; Lorenz Trümper; Anders Osterborg; Ruth Pettengell; Marek Trneny; Kevin Imrie; David Ma; Devinder Gill; Jan Walewski; Pier-Luigi Zinzani; Rolf Stahel; Stein Kvaloy; Ofer Shpilberg; Ulrich Jaeger; Mads Hansen; Tuula Lehtinen; Armando López-Guillermo; Claudia Corrado; Adriana Scheliga; Noel Milpied; Myriam Mendila; Michelle Rashford; Evelyn Kuhnt; Markus Loeffler
Journal:  Lancet Oncol       Date:  2006-05       Impact factor: 41.316

4.  Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.

Authors:  Deborah A Thomas; Stefan Faderl; Susan O'Brien; Carlos Bueso-Ramos; Jorge Cortes; Guillermo Garcia-Manero; Francis J Giles; Srdan Verstovsek; William G Wierda; Sherry A Pierce; Jianqin Shan; Mark Brandt; Fredrick B Hagemeister; Michael J Keating; Fernando Cabanillas; Hagop Kantarjian
Journal:  Cancer       Date:  2006-04-01       Impact factor: 6.860

5.  Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.

Authors:  P Feugier; A Van Hoof; C Sebban; P Solal-Celigny; R Bouabdallah; C Fermé; B Christian; E Lepage; H Tilly; F Morschhauser; P Gaulard; G Salles; A Bosly; C Gisselbrecht; F Reyes; B Coiffier
Journal:  J Clin Oncol       Date:  2005-05-02       Impact factor: 44.544

6.  Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents.

Authors:  Mitchell S Cairo; Mary Gerrard; Richard Sposto; Anne Auperin; C Ross Pinkerton; Jean Michon; Claire Weston; Sherrie L Perkins; Martine Raphael; Keith McCarthy; Catherine Patte
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

7.  Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients.

Authors:  Catherine Patte; Anne Auperin; Mary Gerrard; Jean Michon; Ross Pinkerton; Richard Sposto; Claire Weston; Martine Raphael; Sherrie L Perkins; Keith McCarthy; Mitchell S Cairo
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

8.  The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95.

Authors:  Wilhelm Woessmann; Kathrin Seidemann; Georg Mann; Martin Zimmermann; Birgit Burkhardt; Ilske Oschlies; Wolf-Dieter Ludwig; Thomas Klingebiel; Norbert Graf; Bernd Gruhn; Heribert Juergens; Felix Niggli; Reza Parwaresch; Helmut Gadner; Hansjoerg Riehm; Martin Schrappe; Alfred Reiter
Journal:  Blood       Date:  2004-10-14       Impact factor: 22.113

9.  EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma.

Authors:  Hanneke C Kluin-Nelemans; Jules L Coenen; James E Boers; Gustaaf W van Imhoff; Stefano Rosati
Journal:  Blood       Date:  2008-05-23       Impact factor: 22.113

10.  Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.

Authors:  D G Maloney; T M Liles; D K Czerwinski; C Waldichuk; J Rosenberg; A Grillo-Lopez; R Levy
Journal:  Blood       Date:  1994-10-15       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.